Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome
Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome
复制标题
DOI：
10.1182/blood-2004-03-1209
复制
发表时间：
2004-11-01
期刊：
影响因子：
20.3
通讯作者：
Jack, AS
中科院分区：
文献类型：
--
作者：
Barrans, SL;Fenton, JAL;Jack, AS
FOXP1（Forkhead box-P1）是一种翼状螺旋转录因子，在静息和激活的 B 细胞中差异表达。 FOXP1 表达已在弥漫性大 B 细胞淋巴瘤 (DLBCL) 的子集中得到证实，并且在非生发中心 (non-GC)、活化的 B 细胞类型中更为常见；然而，其预后意义尚不确定。我们使用标准免疫细胞化学分析了 126 名淋巴结性 DLBCL 患者的淋巴结（之前根据 GC 和 BCL2 状态进行分类）的 FOXP1 蛋白表达。在 126 名 DLBCL 患者中，有 23 名患者表现出均匀的高 FOXP1 表达。这种高水平的表达几乎完全局限于缺乏 GC 表型的患者、在缺乏 t(14;18) 的情况下表达 MUM-1 和 BCL2 的患者，以及被确定为预后本来就很差的患者中预后特别差的亚组。所提供的数据表明 FOXP1 高表达是 DLBCL 的独立预后因素。 (C) 2004 年，美国血液学会。
FOXP1 (Forkhead box-P1) is a winged-helix transcription factor that is differentially expressed in resting and activated B cells. FOXP1 expression has been demonstrated in a subset of diffuse large B-cell lymphomas (DLBCLs) and is more common in the nongerminal center (non-GC), activated B-cell type; however, its prognostic significance is uncertain. We analyzed presentation lymph nodes from 126 patients with nodal DLBCL, previously classified according to GC and BCL2 status, for FOXP1 protein expression using standard immunocytochemistry. Uniform high FOXP1 expression was demonstrated in 23 of 126 patients with DLBCL. This high level of expression was almost exclusively confined to patients who lacked the GC phenotype, who expressed MUM-1 and BCL2 in the absence of t(14;18), and who were identified as a subgroup of patients with particularly poor outcomes in a group with already poor prognoses. The data presented suggest that high FOXP1 expression is an independent prognostic factor in DLBCL. (C) 2004 by The American Society of Hematology.